Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the upcoming AACR meeting in Atlanta.
At the meeting, the Company plans to unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.
CBX-11 combines Cybrexa’s proprietary alphalex™ tumor targeting technology with an already-approved oral small molecule PARP inhibitor. more